Close this search box.



June 25, 2024
IGC Pharma’s TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer’s Disease

Potomac, Md., June 25, 2024 – IGC Pharma, Inc. (NYSE American: IGC) ("IGC" or the "Company") today announced encouraging preclinical results in an Alzheimer’s mouse model demonstrating the potential of the Company’s therapeutic candidate, TGR-63, to combat Alzheimer's disease.

Ram Mukunda, CEO of IGC Pharma

“These preclinical results for TGR-63 are highly encouraging. The significant reduction in amyloid plaque burden in an Alzheimer’s mouse model observed in this study suggests TGR-63 has the potential to be a transformative treatment for Alzheimer’s disease. TGR-63 is filed for patent protection in U.S. patent application (USPTO Patent Application Number: 18/006,578), further strengthening its potential value. We are committed to advancing TGR-63 through clinical trials to determine its efficacy and safety in human patients, offering new hope for the 50 million individuals affected by this devastating illness”, said Ram Mukunda, CEO of IGC Pharma.

Alzheimer’s disease is characterized by the buildup of abnormal protein aggregates in the brain, including amyloid plaques. These plaques are thought to play a major role in the cognitive decline and memory loss associated with the disease. Current medications for Alzheimer’s primarily focus on reducing or clearing amyloid plaque, highlighting its importance as a therapeutic target.

In a mouse model of Alzheimer’s, TGR-63 treatment led to a substantial reduction of amyloid plaque. Compared to untreated mice, TGR-63 treatment reduced plaque deposits by 78% in the cortex, a critical brain region for memory and cognition, and by 85% in the hippocampus, which plays a central role in learning and memory. These findings suggest TGR-63’s potential to slow or even reverse the progression of Alzheimer’s disease.

Prior to in vivo studies, TGR-63 demonstrated its ability to disrupt the formation of toxic amyloid beta (Aβ42) aggregates in cell cultures and increase the viability of neuronal cells exposed to Aβ42, indicating potential neuroprotective effects. TGR-63’s unique structure allows it to interact with amyloid beta aggregates, potentially disrupting their structure and promoting their breakdown or clearance by the body’s natural waste disposal systems. This could ultimately lead to a reduction in plaque burden in the brain, although there can be no assurance. The positive results from these preclinical studies could pave the way for advancing TGR-63 through clinical trials. IGC Pharma expects to begin a Phase 1 trial for TGR-63 in 2025, although there can be no assurance.

About IGC Pharma, Inc.

IGC Pharma Inc. (“IGC”) is focused on Alzheimer’s disease, developing innovative solutions to address this devastating illness. The Company’s mission is to transform the landscape of Alzheimer’s treatment with a robust pipeline of five promising drug candidates. IGC-AD1 and LMP target the hallmarks of Alzheimer’s disease, including neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is undergoing a Phase 2 clinical trial for Agitation in dementia associated with Alzheimer’s (, NCT05543681). 

TGR-63 disrupts the progression of Alzheimer’s by targeting Aβ plaques. IGC-M3, currently in preclinical development, aims to inhibit the aggregation of Aβ plaques, potentially impacting early-stage Alzheimer’s. IGC-1C, also in preclinical stages, targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer’s therapy. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (“AI”) for Alzheimer’s research. Their AI projects encompass various areas, including clinical trial optimization and early detection of Alzheimer’s.

Forward-looking Statements

This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA’s general position regarding Cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma’s U.S. Securities and Exchange Commission (“SEC“) filings. IGC Pharma incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on July 7, 2023, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.



IMS Investor Relations

Walter Frank/Rosalyn Christian
(203) 972-9200


Janet Vasquez
(212) 645-5498